News
UPB
6.30
-2.93%
-0.19
Weekly Report: what happened at UPB last week (0324-0328)?
Weekly Report · 3d ago
Weekly Report: what happened at UPB last week (0317-0321)?
Weekly Report · 03/24 12:34
Weekly Report: what happened at UPB last week (0310-0314)?
Weekly Report · 03/17 12:51
Upstream Bio Q3 Sales $613.00K Miss $686.67K Estimate
Benzinga · 03/12 11:21
Press Release: Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Dow Jones · 03/12 11:12
*Upstream Bio 4Q Loss $21.2M >UPB
Dow Jones · 03/12 11:09
*Upstream Bio: Runway Through 2027 >UPB
Dow Jones · 03/12 11:09
Press Release: Upstream Bio Reports Fourth -2-
Dow Jones · 03/12 11:00
Weekly Report: what happened at UPB last week (0303-0307)?
Weekly Report · 03/10 12:53
Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)
TipRanks · 03/04 11:49
Weekly Report: what happened at UPB last week (0224-0228)?
Weekly Report · 03/03 12:52
Weekly Report: what happened at UPB last week (0217-0221)?
Weekly Report · 02/24 12:52
Weekly Report: what happened at UPB last week (0210-0214)?
Weekly Report · 02/17 12:47
Weekly Report: what happened at UPB last week (0203-0207)?
Weekly Report · 02/10 12:37
Weekly Report: what happened at UPB last week (0127-0131)?
Weekly Report · 02/03 12:45
Weekly Report: what happened at UPB last week (0120-0124)?
Weekly Report · 01/27 12:50
Weekly Report: what happened at UPB last week (0113-0117)?
Weekly Report · 01/20 12:35
Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)
TipRanks · 01/14 11:57
Weekly Report: what happened at UPB last week (0106-0110)?
Weekly Report · 01/13 12:37
More
Webull provides a variety of real-time UPB stock news. You can receive the latest news about UpStream Bio Inc. through multiple platforms. This information may help you make smarter investment decisions.
About UPB
More
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin. The Company has advanced this highly potent monoclonal antibody into separate Phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and plans to initiate development of chronic obstructive pulmonary disease (COPD).